XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Provided By GlobeNewswire
Last update: Dec 2, 2024
Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets
Read more at globenewswire.comNASDAQ:XOMA (6/18/2025, 2:01:00 PM)
23.73
-0.2 (-0.84%)
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
NASDAQ:XOMAP (6/18/2025, 1:24:03 PM)
25.7
+0.05 (+0.19%)
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
NASDAQ:XOMAO (6/18/2025, 1:54:55 PM)
25.34
+0.1 (+0.4%)
Find more stocks in the Stock Screener
